Supplemental Annuity Collective Trust of NJ continued to hold its stake in shares of Merck & Company, Inc. (NYSE:MRK) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,000 shares of the company’s stock at the end of the 2nd quarter. Merck & comprises 1.1% of Supplemental Annuity Collective Trust of NJ’s portfolio, making the stock its 19th biggest holding. Supplemental Annuity Collective Trust of NJ’s holdings in Merck & were worth $2,564,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Merck & by 133.4% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock worth $9,165,000 after acquiring an additional 82,454 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Merck & by 2.6% in the second quarter. Russell Investments Group Ltd. now owns 4,206,648 shares of the company’s stock worth $269,678,000 after acquiring an additional 107,201 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH grew its holdings in shares of Merck & by 41.9% in the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 296,294 shares of the company’s stock worth $19,028,000 after acquiring an additional 87,443 shares during the period. Stevens Capital Management LP bought a new stake in shares of Merck & in the first quarter worth $15,126,000. Finally, Bridges Investment Management Inc. grew its holdings in shares of Merck & by 18.0% in the second quarter. Bridges Investment Management Inc. now owns 46,436 shares of the company’s stock worth $2,976,000 after acquiring an additional 7,070 shares during the period. 72.91% of the stock is owned by institutional investors.
WARNING: “Supplemental Annuity Collective Trust of NJ Has $2,564,000 Holdings in Merck & Company, Inc. (MRK)” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://sportsperspectives.com/2017/10/13/supplemental-annuity-collective-trust-of-nj-has-2564000-holdings-in-merck-company-inc-mrk.html.
Several analysts recently commented on MRK shares. Cowen and Company reaffirmed a “hold” rating and issued a $70.00 price objective on shares of Merck & in a report on Friday, September 1st. Zacks Investment Research lowered Merck & from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Jefferies Group LLC reiterated a “sell” rating and set a $52.00 target price on shares of Merck & in a research report on Sunday, August 20th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $74.00 target price (up from $70.00) on shares of Merck & in a research report on Thursday, July 27th. Finally, BMO Capital Markets set a $70.00 target price on Merck & and gave the company a “buy” rating in a research report on Wednesday. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $70.13.
Merck & Company, Inc. (NYSE MRK) opened at 63.83 on Friday. Merck & Company, Inc. has a 12 month low of $58.29 and a 12 month high of $66.80. The stock has a market capitalization of $174.09 billion, a P/E ratio of 34.56 and a beta of 0.80. The stock has a 50 day moving average price of $64.51 and a 200 day moving average price of $63.70.
Merck & (NYSE:MRK) last posted its earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The firm had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. During the same period last year, the firm earned $0.93 EPS. The company’s quarterly revenue was up .9% on a year-over-year basis. Equities analysts predict that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, October 6th. Stockholders of record on Friday, September 15th were given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date of this dividend was Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is presently 76.11%.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.